Drugs Made In America Acquisition II Corp (DMII) is a blank check special purpose acquisition company incorporated on August 23, 2024, that exists solely to identify and complete an initial business combination with a target business. It generates no operating revenue. The company raised proceeds through an IPO and concurrent private placement of Private Placement Units, placing $500,000,000 into a trust account established at Continental Stock Transfer & Trust Company as of September 26, 2025. Those trust funds, representing approximately $10.00 per public share, are held until completion of a business combination, shareholder-approved amendments, or liquidation. The company intends to fund its initial business combination using cash from the trust, equity, debt, or a combination. As of December 31, 2025, DMII had no operations. CEO Roger Bendelac and CFO Saleem Elmasri signed the 10-K filed April 15, 2026. The prior executive offices were in Fort Lauderdale, FL; current offices are at 420 Lexington Avenue, Suite 1402, New York, NY.

Revenue model

No operating revenue. The company earns interest on trust account funds, which may be released to pay taxes. All other trust proceeds are restricted until completion of a business combination or liquidation.

Products and services

Blank check SPAC structure. IPO units and Private Placement Units issued to raise capital. Trust account holding $500,000,000 as of September 26, 2025, managed by Continental Stock Transfer & Trust Company.

Customers and end markets

Public shareholders hold shares redeemable at approximately $10.00 per share. Target end market is unspecified; the filing indicates the company may seek targets that are financially unstable or in early stages of development or growth.

Value-chain role

Pre-combination acquisition vehicle. Raises public capital, holds funds in trust, and seeks a merger or acquisition target to effectuate an initial business combination.

Geographic exposure

Incorporated and operating in the United States. Current executive office at 420 Lexington Avenue, Suite 1402, New York, NY (as of the 10-K filed April 15, 2026).

Source: SEC 10-K, filed 2026-04-15

Industry: Blank Checks